Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1491-1497

  Yamauchi, Mai ^a   Imajoh ohmi, Shinobu ^a   Shibuya, Masabumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; NEUTRALIZING ANTIBODY; RETINOBLASTOMA PROTEIN; THROMBOSPONDIN 1;

ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE; COCULTURE TECHNIQUES; ENDOTHELIUM, VASCULAR; GROWTH INHIBITORS; HUMANS; KERATINOCYTES; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; UMBILICAL VEINS;

EID: 34547768293     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00534.x     Document Type: Article

References (30)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Eng J Med 1991; 285: 1182-6.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
3. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
4. Kiba A, Sagara H, Hara T, Shibuya M. VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice. Biochem Biophys Res Commun 2003; 301: 371-7.
5. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004; 112: 496-507.
6. Kiyono M, Shibuya M. Bone morphogenetic protein 4 mediates apoptosis of capillary endothelial cells during rat pupillary membrane regression. Mol Cell Biol 2003; 23: 4627-36.
7. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005; 65: 3967-79.
8. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 1996; 7: 213-21.
9. Takahashi T, Shibuya M. The 230-kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997; 14: 2079-89.
10. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995; 10: 135-47.
11. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells. EMBO J 2001; 20: 2768-78.
12. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, Wheatley DN. An in vitro model of angiogenesis: Basic features. Angiogenesis 1999; 3: 335-44.
13. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003; 22: 63-71.
14. Crawford SE, Stellmach V, Murphy-Ullrich JE et al. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 1998; 93: 1159-70.
15. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138: 707-17.
16. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41-8.
17. Lawler J, Sunday M, Thibert V et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 1998; 101: 982-92.
18. Volpert OV, Zaichuk T, Zhou W et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8: 349-57.
19. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 2005; 168: 643-53.
20. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by two independent regions within the type 1 repeats. Circulation 1999; 100: 1423-31.
21. Yano K, Kadoya K, Kajiya K, Hong YK, Detmer M. Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 2005; 152: 115-21.
22. Streit M, Velasco P, Riccardi L et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 2000; 19: 3272-82.
23. Febbraio M, Abumrad NA, Hajjar DP et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999; 274: 19 055-62.
24. Nakamura S, Muro H, Suzuki S et al. Immunohistochemical studies on endothelial cell phenotype in hepatocellular carcinoma. Hepatology 1997; 26: 407-15.
25. Sund M, Hamano Y, Sugimoto H et al. Function of endogenous inhibitor of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005; 102: 2934-9.
26. Huang H, Campbell SC, Bedford DF et al. Peroxisome proliferator-activated receptor γ ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Can Res 2004; 2: 541-50.
27. Volpert OV, Dameron KM, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 1997; 14: 1495-502.
28. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol 2004; 36: 961-8.
29. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004; 36: 1070-8.
30. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-β by thrombospondin-1: Mechanisms and physiology. Cytokine Growth Factor Rev 2000; 11: 59-69.